SINGAPORE—In a strategic move to strengthen its position in the global medical device market, Edwards Lifesciences has announced the acquisition of intellectual property and commercial rights to Genesis MedTech’s J-VALVE transcatheter aortic valve system. This acquisition highlights Edwards Lifesciences’ commitment to advancing cardiovascular care and underscores its ongoing expansion strategy.
Genesis MedTech, a pioneer in the development of innovative medical devices, will receive an undisclosed upfront payment and is eligible for sales-related milestone payments as part of the deal. The company retains exclusive rights to develop, manufacture, and market the product within China, ensuring its continued growth in the domestic market.
Edwards Lifesciences, which dominates 70% of the global valve market, previously invested USD 180 million in Genesis MedTech, recognizing the potential of its product and market development. The J-VALVE system, featuring Genesis MedTech’s T1000 exatecan linker payload technology, is designed to enhance the bystander effect, improve linker stability, and potentially overcome drug resistance mechanisms, offering a significant advancement in the treatment of aortic valve diseases.
The clinical trial data supporting this acquisition demonstrated an overall response rate of 83% and a complete response rate of 63% in patients treated with the J-VALVE system, with a median duration of response of 21.4 months. The acquisition is expected to bolster Edwards Lifesciences’ product lineup and provide a new treatment option for patients suffering from aortic valve disorders.- Flcube.com
